Jane Street’s Corvus Pharmaceuticals CRVS Stock Holding History

Jane Street’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$613K	Buy	41,900 +26,200	+167%	+$418K	﹤0.01%	7563
2025 Q4	$121K	Buy	+15,700	New	+$124K	﹤0.01%	10074
2025 Q2	–	Sell	-12,200	Closed	-$38.8K	–	9789
2025 Q1	$38.8K	Sell	12,200 -57,000	-82%	-$268K	﹤0.01%	9054
2024 Q4	$370K	Buy	+69,200	New	+$517K	﹤0.01%	7375
2022 Q1	–	Sell	-10,300	Closed	-$25K	–	10377
2021 Q4	$25K	Sell	10,300 -75,000	-88%	-$291K	﹤0.01%	9738
2021 Q3	$413K	Buy	+85,300	New	+$252K	﹤0.01%	7626

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jane Street's CRVS Position: Q1 2026 in Review

Jane Street reduced its Corvus Pharmaceuticals (CRVS) stake by 88% in Q1 2026, selling an estimated $5.33M and leaving 44,473 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #7424.

Jane Street first reported a position in CRVS in Q3 2021 and has held it in 11 quarters since. The position peaked at $2.91M in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

Jane Street held 44,473 shares of Corvus Pharmaceuticals worth $651K as of Q1 2026.
Jane Street sold 333,824 Corvus Pharmaceuticals shares in Q1 2026, an estimated $5.33M.
Corvus Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7424 holding.
Jane Street first reported a position in Corvus Pharmaceuticals in Q3 2021 and has held it in 11 quarters since.
Jane Street's Corvus Pharmaceuticals position peaked at $2.91M in Q4 2025.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.